AI Insight
This phase 4 randomized clinical trial in Uganda compared fractional doses (one-fifth and one-half) of the 17DD yellow fever vaccine to full doses in children aged 9-23 months. Both fractional doses demonstrated non-inferiority to full doses in achieving initial seroconversion, meaning they were equally effective at generating immune responses. The study provides evidence that reduced vaccine doses can maintain immunological efficacy in young children.
Why it matters
These findings support the use of fractional-dose yellow fever vaccination strategies during vaccine shortages or outbreak situations, allowing limited vaccine supplies to protect more children. This approach could be particularly valuable in resource-limited settings where vaccine availability is constrained and young children are at risk during yellow fever outbreaks.
Both fractional doses of 17DD yellow fever vaccine were non-inferior to full doses in inducing initial seroconversion. The results support the use of fractional dose yellow fever vaccines among young children for outbreak response during supply shortages.